AU743544B2 - Selective factor Xa inhibitors - Google Patents
Selective factor Xa inhibitors Download PDFInfo
- Publication number
- AU743544B2 AU743544B2 AU49047/97A AU4904797A AU743544B2 AU 743544 B2 AU743544 B2 AU 743544B2 AU 49047/97 A AU49047/97 A AU 49047/97A AU 4904797 A AU4904797 A AU 4904797A AU 743544 B2 AU743544 B2 AU 743544B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- aryl
- alkyl
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 141
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 47
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 208000007536 Thrombosis Diseases 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000003146 anticoagulant agent Substances 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 230000015271 coagulation Effects 0.000 claims description 14
- 238000005345 coagulation Methods 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 206010047249 Venous thrombosis Diseases 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 206010038563 Reocclusion Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010002388 Angina unstable Diseases 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 4
- 208000007814 Unstable Angina Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 3
- 206010014498 Embolic stroke Diseases 0.000 claims description 3
- 208000021328 arterial occlusion Diseases 0.000 claims description 3
- 208000015294 blood coagulation disease Diseases 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000009424 thromboembolic effect Effects 0.000 claims description 3
- 210000005166 vasculature Anatomy 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 125000001424 substituent group Chemical group 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 23
- 239000003112 inhibitor Substances 0.000 description 21
- 108090000190 Thrombin Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 229960004072 thrombin Drugs 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- -1 -COOR 1 0 -CONRiOR" Chemical group 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940127219 anticoagulant drug Drugs 0.000 description 10
- 239000000651 prodrug Chemical class 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 7
- 108010014806 prothrombinase complex Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- WXEHBUMAEPOYKP-UHFFFAOYSA-N methylsulfanylethane Chemical compound CCSC WXEHBUMAEPOYKP-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940122388 Thrombin inhibitor Drugs 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- VJZRBVVLWLEXBB-VROPFNGYSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[2-[(4-methylphenyl)sulfonylamino]acetyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCC1 VJZRBVVLWLEXBB-VROPFNGYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 241000237654 Haementeria ghilianii Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000005024 alkenyl aryl group Chemical group 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 108010018472 chromozym TH Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012453 solvate Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 229960000103 thrombolytic agent Drugs 0.000 description 3
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 101710163968 Antistasin Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010074105 Factor Va Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000237664 Haementeria officinalis Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000014763 coagulation protein disease Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001147657 Ancylostoma Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710200938 Coagulation factor X inhibitor Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241001505404 Deinagkistrodon acutus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710194146 Ecotin Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710141959 Ghilanten Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101000941926 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Carboxypeptidase Y inhibitor Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- XYWDPYKBIRQXQS-UHFFFAOYSA-N di-isopropyl sulphide Natural products CC(C)SC(C)C XYWDPYKBIRQXQS-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- QUFUZPOMGMZNNL-UHFFFAOYSA-N lithium;2h-1,3-thiazol-2-ide Chemical compound [Li+].C1=CS[C-]=N1 QUFUZPOMGMZNNL-UHFFFAOYSA-N 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical class COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 238000003614 protease activity assay Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 1
- BJEDOFBBFSVQCP-UHFFFAOYSA-N tert-butyl 4-(4-ethoxy-4-oxobutyl)piperidine-1-carboxylate Chemical compound CCOC(=O)CCCC1CCN(C(=O)OC(C)(C)C)CC1 BJEDOFBBFSVQCP-UHFFFAOYSA-N 0.000 description 1
- JONJYKFTSVMZOT-SOFGYWHQSA-N tert-butyl 4-[(e)-4-ethoxy-4-oxobut-2-enyl]piperidine-1-carboxylate Chemical compound CCOC(=O)\C=C\CC1CCN(C(=O)OC(C)(C)C)CC1 JONJYKFTSVMZOT-SOFGYWHQSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 98/16525 PCT/US97/18647 Selective Factor Xa Inhibitors Field of the Invention This invention relates to novel heterocyclic compounds which are potent and highly selective inhibitors of factor Xa or factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation thrombin, fVIIa, fIXa) or the fibrinolytic cascades plasminogen activators, plasmin).
Background of the Invention Blood coagulation protects mammalian species when the integrity of the blood vessel wall is damaged and uncontrolled loss of blood threatens survival. Coagulation, resulting in the clotting of blood is an important component of hemostasis. Under normal hemostatic circumstances, there is maintained an acute balance of clot formation and clot removal (fibrinolysis). The blood coagulation cascade involves the conversion of a variety of inactive enzymes (zymogens) into active enzymes which ultimately convert the soluble plasma protein fibrinogen into an insoluble matrix of highly cross-linked fibrin.
See Davie, et al., "The Coagulation Cascade: Initiation, Maintenance and Regulation" Biochemistry 30:10363-10370 (1991). Blood platelets which adhere to damaged blood vessels are activated and incorporated into the clot and thus play a major role in the initial formation and stabilization of hemostatic "plugs". In certain diseases of the cardiovascular system, deviations from normal hemostasis push the balance of clot formation and clot dissolution towards life-threatening thrombus formation when thrombi occlude blood flow in coronary vessels (myocardial infarctions) or limb and pulmonary veins (venous thrombosis). Although platelets and blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.
A key enzyme in the coagulation cascade as well as in hemostasis, is thrombin.
Thrombin is intimately involved in the process of thrombus formation, but under normal WO 98/16525 PCT/US97/18647 circumstances can also play an anticoagulant role in hemostasis through its ability to convert protein C into activated protein C in a thrombomodulin-dependent manner.
Thrombin plays a central role in thrombosis through its ability to catalyze the penultimate conversion of fibrinogen into fibrin and through its potent platelet activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5:411-436 (1994). The major classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e.
heparins, low-molecular weight heparins and coumarins). Thrombin is generated at the convergence of the intrinsic and extrinsic coagulation pathways by the prothrombinase complex. The prothrombinase complex is formed when activated Factor X (factor Xa) and its non-enzymatic cofactor, factor Va assemble on phospholipid surfaces in a Ca 2 dependent fashion as reviewed by Mann, et al, "Surface-Dependent Reactions of the Vitamin K-Dependent Enzymes", Blood 76:1-16 (1990). The prothrombinase complex converts the zymogen prothrombin into the active procoagulant thrombin.
The location of the prothrombinase complex at the convergence of the intrinsic and extrinsic coagulation pathways, and the significant amplification ofthrombin generation (393,000-fold over uncomplexed factor Xa) mediated by the complex at a limited number of targeted catalytic units present at vascular lesion sites, suggests that inhibition of thrombin generation is an ideal method to block uncontrolled procoagulant activity.
Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin.
Plasma contains an endogenous inhibitor of both the factor Vila-tissue factor (TF) complex and factor Xa called tissue factor pathway inhibitor (TFPI). TFPI is a Kunitztype protease inhibitor with three tandem Kunitz domains. TFPI inhibits the TF/fVIIa complex in a two-step mechanism which includes the initial interaction of the second Kunitz domain of TFPI with the active site of factor Xa, thereby inhibiting the WO 98/16525 PCT/US97/18647 proteolytic activity of factor Xa. The second step involves the inhibition of the TF/fVIIa complex by formation of a quaternary complex TF/fVIIa/TFPI/fXa as described by Girard, et al., "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor", Nature 338:518-520 (1989).
Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. U. S. Patent No. 4,588,587 awarded to Gasic, describes anticoagulant activity in the saliva of the Mexican leech, Haementeria officinalis. A principal component of this saliva is shown to be the polypeptide factor Xa inhibitor, antistasin, by Nutt, et al., "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol. Chem.
263:10162-10167 (1988).
Another potent and highly specific inhibitor of Factor Xa, tick anticoagulant peptide, has been isolated from the whole body extract of the soft tick Ornithidoros moubata, as reported by Waxman, et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa", Science 248:593-596 (1990).
Other polypeptide type inhibitors of factor Xa have been reported including the following citations by: Condra, et al., "Isolation and Structural Characterization of a Potent Inhibitor of Coagulation Factor Xa from the Leech Haementeria ghilianii", Thromb. Haemost. 61:437-441 (1989); Blankenship, et al., "Amino Acid Sequence of Ghilanten: Anti-coagulant-antimetastatic Principle of the South American Leech, Haementeria ghilianii", Biochem. Biophys. Res. Commun. 166:1384-1389 (1990); Brankamp, et al., "Ghilantens: Anticoagulants, Antimetastatic Proteins from the South American Leech Haementeria ghilianii", J. Lab. Clin. Med. 115:89-97 (1990); Jacobs, et al., "Isolation and Characterization of a Coagulation Factor Xa Inhibitor from Black Fly Salivary Glands", Thromb. Haemost. 64:235-238 (1990); Rigbi, et al., "Bovine Factor Xa Inhibiting Factor and Pharmaceutical Compositions Containing the Same", European Patent Application, 352,903 (1990); Cox, "Coagulation Factor X Inhibitor From the Hundred-pace Snake Deinagkistrodon acutus venom", Toxicon 31:1445-1457 (1993); WO 98/16525 PCT/US97/18647 Cappello, et al., "Ancylostoma Factor Xa Inhibitor: Partial Purification and its Identification as a Major Hookworm-derived Anticoagulant In Vitro", J. Infect. Dis.
167:1474-1477 (1993); Seymour, et al., "Ecotin is a Potent Anticoagulant and Reversible Tight-binding Inhibitor of Factor Xa", Biochemistry 33:3949-3958 (1994).
Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, et al., "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", Thromb. Res.
19:339-349 (1980); Turner, et al., "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", Biochemistry 25:4929-4935 (1986); Hitomi, et al., "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", Haemostasis 15:164-168 (1985); Sturzebecher, et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", Thromb. Res. 54:245-252 (1989); Kam, et al., "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", Biochemistry 27:2547-2557 (1988); Hauptmann, et al., "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", Thromb.
Haemost. 63:220-223 (1990); Miyadera, et al., Japanese Patent Application JP 6327488 (1994); Nagahara, et al., "Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", J. Med. Chem. 37:1200-1207 (1994); Vlasuk, et al., "Inhibitors of Thrombosis" European Patent Application, WO 93/15756 (1993); and Brunck, et al., "Novel Inhibitors of Factor Xa", European Patent Application, WO 94/13693 (1994). Al-obeidi, et al., "Factor Xa Inhibitors", WO patent 95/29189, discloses pentapeptide X1-Y-I-R-X2 derivatives as factor Xa inhibitors. Said compounds are useful for inhibiting blood clotting in the treatment of thrombosis, stroke, and myocardial infarction.
WO 96/18644 to Tamura, et al., describes aromatic heterocyclic thrombin inhibitors.
WO 95/35313 to Semple, et al., pertains to 3-amino-2-oxo-l-piperidineacetic derivative thrombin inhibitors.
05/12 '01 17:10 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS i1014 4a EP 0,512,831 and US Patent No. 5,281,585, both to Duggan et cii., describe fibrinogen receptor antagonists.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.
STJMN4AR OF THE ENVENTION Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
05/12 '01 17:10 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS [6015 The present invention relates to novel pepide and peptide mimetic analogs, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives.
In another aspect, the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. These compositions are useful as potent and specific inhibitors of blood coagulation in mammals.
In yet another aspect, the invention relates to methods of using these inhibitors as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial to infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intavascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. These compositions may optionally include anticoagulants, S* antiplatelet agents, and thrombolytic agents.
In other aspects of the invention compounds are provided which are useful as diagnostic reagents In preferred embodiments, the present invention provides compounds of general formula 1:
E
K
H)A-(H)
1 0 (CH 2 )p
ACH
2 )mW-(CH 2 )n N N, (I) WO 98/16525 PCT/US97/18647 Wherein: R' is H, C 1 6 alkyl, C 3 .6cycloalkyl, CI.
3 alkylaryl, Ci.3alkyl-C 3 8 cycloalkyl or aryl and
R
2 is H, C 1 .6alkyl, or R' and R 2 are taken together to form a carbocyclic ring; m is an integer from 0-3; n is an integer from 0-6; p is an integer from 0-4; s is an integer from 0-2; q is an integer from 0-2; A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; R 3
-NR
3
R
4
NR
15 N NR3R 16 NR3R17
R
14
NR
15
NR
15
NR
1 NR4 R16 and S, NRR17 where R 3
R
4
R
1 4 and R 1 5 are independently selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and Ci4alkylaryl; R 16 is selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and Cl4alkylaryl, or can be taken together with R' 4 or R 1 5 to form a 5-6 membered ring; and R 1 7 is selected from the group consisting of H, -OH, CI.
6 alkyl, aryl and Ci4alkylaryl, or can be taken together with R 1 5 to form a 5-6 membered ring; W is C 1 6 alkyl, C 3 8 cycloalkyl, CI.
6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; K is selected from the group consisting of a direct link, C 3 8 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; 05/12 '01 17:10 FAX 61 2 9810 8200 F.B. RICE CO. 4 PATENTS Z016 E is selected from the group consisting of R 2 6
-NR
6
R
7 NR9 NR2 \N JKNR26 R "NR A28
NR
29 NR9 NR29 RoandJj RI* )L Rz' NlR R~28' where Rt 6 R?1, R and R are independently selected from the group consisting of H, -OH, C 14 alkyl, aryl and C 1 .alkylaryl; R is selected from the group consisting of H,
C
1 aalkyl, aryl and C 1 4 alkylaryL or can be taken together with RL or.R to form a 5-6' membered ring; and R" is selected from the group consisting ofH, C4alkyl, aryl and
C
1 4 alkylaryl, or can be taken together with R9 to form a 5-6 membered ring-, with the proviso that when E is R 6 then K must contain at least one N atom; Y is selected from the group consisting of H,
H
3 9 9* 9 *99OR9' H 3 0 '13 oIjfHa H nd R
CH
CH3
CH
3
CH
3 where R" and R13 are independently selected from the group consisting of H, C13alkyl and aryl; and G is H, -COOR' 0 -CONW k! -CF3, -CF 2
CF
3 or a group having the formula- NU or
L
where:
R
2 is selected from the group consisting of H, C 6 alkyl, Cz 2 -alkenyl, Coalkylaryl,
C
24 alkenylaryl, C 0 6alkylheterocyclo, C 2 4 alkenytheterocyclo, -CF 3 and -CF 2
CF
3 WO 98/16525 PCT/US97/18647 J is -SO 2 or -NR 5 where R 5 is H, C 16 alkyl or benzyl; and L is selected from the group consisting of:
R
8
R
R
8
(CH
2 )r 1 I and
R
7 R9 a C6-Io heterocyclic ring system substituted by R 8 and R 9 and containing 1-4 heteroatoms selected from N, S and 0; where r is an integer from 0-2; R 6 and R 7 are independently selected from the group consisting of H, C 1 -6alkyl, aryl, C 1 6 alkylaryl, -COOR 1 0 -CONRiOR", -CN and -CF 3
R
8 and R 9 are independently selected from the group consisting of H, C 1 6 alkyl, aryl, C1.6alkylaryl, C i.alkyloxy, halogen, -NR'RI 1 -NR'OCOR", -O-R 1 0
-O-COR
10 -COOR'O, -CONR'OR", -CN, -CF 3 -SOzNR'OR" and
C
1 .6alkyl-O-R 0 and R' 1 and R 11 are independently selected from the group consisting of H, Ci.6alkyl, C 1 .3alkylaryl and aryl; U is or and V is or with the proviso that at least one of U or V is or and all optical isomers thereof.
DETAILED DESCRIPTION OF THE INVENTION Definitions In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.
The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms.
WO 98/16525 PCT/US97/18647 The term "alkenyl" refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having at least one double bond and having the number of carbon atoms specified.
The term "aryl" refers to an unsubstituted or substituted aromatic ring(s), substituted with one, two or three substituents such as, by way of example and not limitation, C 6 alkoxy, C, 6 alkyl, C 1 6 alkylamino, hydroxy, halogen, cyano hydroxyl, mercapto, nitro (-NO 2 thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy, carboxamide, -NR'COR", -OR, -OCOR, -COOR, -CONR'R", -CF 3
-SO
2 NR'R" and C .6alkyl-OR; aryl, C 6 alkylaryl (where the R groups can be H, C 1 6 alkyl, C -3alkylaryl and aryl), including but not limited to carbocyclic aryl, heterocyclic aryl, biaryl and triaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, C, 6 alkylphenyl, naphthyl, biphenyl. phenanthrenyl, naphthacenyl, and aromatic heterocyclics or heteroaryls, the latter of which is an aryl group containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Aryl groups preferably have 5-14 carbon atoms making up the ring(s) structure, while heteroaryls preferably have 1-4 heteroatoms, with the remaining 4-10 atoms being carbon atoms.
The terms "heterocyclo" and "hetero cyclic ring system" as used herein refer to any saturated or unsaturated mono- or bicyclic ring system, containing from one to four heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur. A typical heterocyclic ring system will have five to ten members, 1-4 of which are heteroatoms.
Typical examples of monocyclic ring systems include piperidinyl, pyrrolidinyl, pyridinyl, piperidonyl, pyrrolidonyl and thiazolyl, while examples of bicyclic ring systems include benzimidazolyl, benzothiazolyl and benzoxazolyl, all of which may be substituted.
The term "carbocyclic ring" as used herein refers to any saturated or unsaturated ring containing from three to six carbon atoms.
The terms "alkylaryl" and "alkenylaryl" as used herein refer to an alkyl group or WO 98/16525 PCT/US97/18647 alkenyl group, respectively, having the number of carbon atoms designated, appended to one, two, or three aryl groups. The term benzyl as used herein refers to -CH 2
-C
6 Hs.
The term "alkoxy" as used herein refers to an alkyl linked to an oxygen atom, such as methoxy, ethoxy, and so forth.
The terms "halogen" as used herein refer to Cl, Br, F or I substituents.
The term "direct link" as used herein refers to a bond directly linking the substituents on each side of the direct link. When two adjacent substituents are defined as each being a "direct link", it is considered to be a single bond.
Two substituents are "taken together to form a 5-6 membered ring" means that an ethylene or a propylene bridge, respectively, is formed between the two substituents.
The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid. succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum bases, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, WO 98/16525 PCT/US97/18647 and tertiary amines, substituted amines including naturally occurring substituted amines.
cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine. histidine, caffeine, procaine, hydrabamine. choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
"Biological property" for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it. The biological properties of the compounds of the present invention can be readily characterized by the methods described in Examples 14 and 15 and by such other methods as are well known in the art.
In addition, the following abbreviations are used in this application: "Boc" refers to t-butoxycarbonyl.
"BOP" refers to benzotriazol-l-yloxy-tris-(dimethylamino) phosphonium hexafluorophosphate.
"DIEA" refers to diisopropylethylamine.
"DMF" refers to N,N-dimethylformamide.
"DMSO" refers to dimethylsulfoxide.
"Et 2 O" refers to diethyl ether.
"EtOAc" refers to ethyl acetate.
"HOAc" refers to acetic acid.
WO 98/16525 PCT/US97/18647 "LDA" refers to lithium diisopropylamide.
"MeOH" refers to methanol.
"MeSEt" refers to methyl ethyl sulfide.
"NaN(TMS) 2 refers to sodium bis-trimethyl silyl amide.
"TFA" refers to trifluoroacetic acid.
"THF" refers to tetrahydrofuran.
"Tos" refers to p-toluenesulfonyl.
In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention. In the processes described above, the final products may, in some cases, contain a small amount of diastereomeric or enantiomeric products; however, these products do not affect their therapeutic or diagnostic application.
In all of the peptides of the invention, one or more amide linkages may optionally be replaced with another linkage which is an isostere such as -CH2NH-,
-CH
2
-CH
2 -CH2CH 2 -CH=CH- (cis and trans), -COCH 2
-CH(OH)CH
2
-CH
2 SO-, and -CH 2
SO
2 This replacement can be made by methods known in the art.
The following references describe preparation of peptide analogs which include these alternative-linking moieties: Spatola, "Peptide Backbone Modifications" (general review) Veg Data, Vol. 1, Issue 3, (March 1983); Spatola, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," (general review) B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Morley, Trends Pharm. Sci. (general review) pp. 463- WO 98/16525 PCT/US97/18647 468 (1980); Hudson, et al., Int. J. Pept. Prot. Res. 14:177-185 (1979) (-CH 2
NH-,
-CH
2
CH
2 Spatola, et al., Life Sci. 38:1243-1249 (1986) (-CH 2 Hann, J. Chem. Soc.
Perkin Trans. I pp.307-314 (1982) cis and trans); Almquist, et al., J Med.
Chem. 23:1392-1398 (1980) (-COCH 2 Jennings-White, et al., Tetrahedron Lett.
23:2533 (-COCH 2 (1982); Szelke, et al., European Application EP 45665; CA:97:39405 (1982) (-CH(OH)CH 2 Holladay, et al., Tetrahedron Lett 24:4401-4404 (1983)
(-CH(OH)CH
2 and Hruby, Life Sci. 31:189-199 (1982) (-CH 2 Preferred Embodiments This invention relates to a new class of peptide derivatives selected from those of general formula I which are potent and specific inhibitors of Xa, their pharmaceutically acceptable compositions thereof, and the methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis:
E
I
H2)s (CH2)q K f 1 CHp
A-(CH
2 )m-W-(CH 2 )n N (I) 0 R' R 2 Wherein: R' is H, Ci.
6 alkyl, C 3 6 cycloalkyl, C 1 .3alkylaryl, CI.
3 alkyl-C 3 8 cycloalkyl or aryl and
R
2 is H, Ci.
6 alkyl, or R' and R 2 are taken together to form a carbocyclic ring; m is an integer from 0-3; n is an integer from 0-6; p is an integer from 0-4; s is an integer from 0-2; q is an integer from 0-2; A is selected from the group consisting of: a five to ten membered heterocyclic ring WO 98/16525 PCTIUS97/18647 system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S. R 3
-NR
3
R
4 N R 15
NR
1 '1 N R 3R16 7 N R 3R17 R'14 NR 1 5 NR 1 5 NR 1 R )K 17 an S,-KN R17 where R 3 R4~, R 1 4 and R1 5 are independently selected from the group consisting of H, -OH, Cl- 6 alkyl,*aryl and C 1 4 alkylaryl; R 1 6 is selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and C 14 alkylaryl, or can be taken together with R' 4 or R5to form a 5-6 membered ring; and R 1 7 is selected from the group consisting of H, -OH, C,- 6 alkyl, aryl and C 14 alkylaryl, or can be taken together with R1 5 to form a 5-6 membered ring; W is C 16 alkyl, C 3 -8cycloalkyl, C 16 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N,O0and S; K is selected from the group consisting of a direct link, C 3 8 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S; E is selected from the group consisting of R 1 6 -NR1 6 R 7
NA
29 NR 29 N NR 26
R
30 IA NR6j A28
NR
29
NR
29 NR 29 ~N>KJ-R 30 31 and R63 where R1 6
R
2 R 28 and R 29 are independently selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and CI-4alkylaryl; R 30 is selected from the group consisting of H, 05/12 '01 17:10 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS 0017
C
14 alkyl, aryl and C- 4 alkylaryl, or can be taken together with R 28 or R to form a 5-6 membered ring; and R 3 is selected from the group consisting of H, C 1 _alkyl, aryl and
C
14 alkylaryl, or can be taken together with R? to form a 5-6 membered ring; with the proviso that when E is R 26 then K must contain at least one N atom; Y is selected from the group consisting ofH,
H
3 ,OR2 B- H 3 0 -O TBOIJGCH H and 013
H
H3.
CH3 where R' 2 and R" are independently selected from the group consisting of H. C-3alkyl and aryl; and 0 is H. -COOR'", -CONR'"R' 9
-C
3
-CF
2
CF
3 or a group having the formul 0 or
L
10 RJ S where: R2o is selected from the group consisting of H, C ralkyl, C 24 allen, C alkylaryl,
C
2 .alkenylaryl, Co, 4 alkylheterocyclo, C2.alkenylheterocyclo, -CF 3 and -CF 2
CF
3 J is 0 or -NR 5 where R' is H, C 1 .alkyl or benzyl; and L is selected from the group consisting of:
R~
R6 -R8 Ra I(C) and R R a Co 6 1 0 heterocyclic ring systemrn substituted by R 8 and R and containing 14 heteroatorns selected from N, S and 0; where r is an integer from 0-2; R' and RC are independently selected from the group consisting of H, Ci4alkyl, aryl, C 14 alkyIaryl, -COOR'o 0 05/12 '01 17:11 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS [1018 99 0 0 699 p.
0 99 9 9 9.
*u 9 9* 0 4
-CONR'
1 -CN and -CF3; R 8 and R 9 are independently selected from the group consisting of H, Ci-alkyl, aryl, Ci 4 alkylaryl, Ci 4 alkyloxy, halogen, -NO 2
-NR'"
11 -NR'iCOR", -O-R 1 -O-COR'O, -COORIO,--CONR i O -CN, -CF 3 -S02NR'OR" and Claalyl-O-R' 0 and R' i and R" are independently selected from the group consisting of tH C.6alkyl, Ci.
3 alkylaryl and aryl; U is or and V is or with the proviso that at least one of U or V is or and all optical isomers thereof.
Preferred R substituents are H and Citalkyl; more preferably H.
R
2 is preferably H.
The integer is preferably from 0-1; more preferably 0.
The integer is preferably from 1-4.
The integer is preferably 3.
The integer is preferably 0.
The integer is preferably from 0-1.
Preferred substituents are R3, -R R,
NR'
s NRh
NRF
2K W and)Q I S
R
3 is preferably H, -OH or C 1 i&alkyl; more preferably H, -OH or methyl.
R4 is preferably H, -OH or C 1 a6alkyl; more preferably H, -OH or methyl, Preferred substituents are C.
4 alkyl, Cs.cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom; more preferably
C,
4 alkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom.
K is preferably a direct link.
WO 98/16525 PCT/US97/18647 In the substituent, it is preferred that R 26
R
27
R
28
R
29
R
30 and R" are independently selected from the group consisting of H and C 1 6 alkyl, more preferably H and methyl. Particularly preferred substituents are -NH 2 -NHC(=NH)-NH, and -SC(=NH)-NH2; more preferably -NHC(=NH)-NH2 and -SC(=NH)-NH,.
Preferred substituents are:
/OR
12
ORB
OR13 0
,G
R
12 is preferably H.
R
1 3 is preferably H.
The substituent is preferably a group having the formula:
N
L
The substituent is preferably or -NR 3
R
5 is preferably H.
The substituent is preferably:
R
8 R9 more preferably:
R
8 R9
R
6 is preferably H.
R
7 is preferably H.
R
8 is preferably H, -O-R 1 0 -COOR'O, -CONR" 1 R" or-CF 3 more preferably H.
WO 98/16525 PCT/US97/18647
R
9 is preferably H, -O-R' 0
-COOR'
0
-CONR'
0 R" or -CF 3 more preferably H.
R1 0 is preferably H.
R" is preferably H.
In one embodiment of the invention, R' and R 2 are H, p=3, s=O, K is a direct link, E is
-NHC(=NH)-NH
2 and Y is -CO-G, where G is a group having the formula:
N
where J and L are as defined above. This is also illustrated as a preferred group of compounds defined by the general structural formula 11 as: HN YNH 2
NH
(CH
2 X) 0
A-(CH
2 2 n Y N" NL 0 H 0 wherein: mn is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2; A is selected from the group consisting of -NRR 4
NR
15
NR'
N )N,<NR3R 16; N R 3R17
NR
15
NR'
5 NR 1 j N> R 16. and N 3 1 where R 4
R"
5 R 1 6 and R 1 7 are independently selected from the group consisting WO 98/16525 PCT/US97/18647 of H, -OH and C,.
6 alkyl; W is Ci.
6 alkyl, C3.
8 cycloalkyl, C 1 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; with the proviso that when A is R 3 then W must contain at least one N atom; J is -SO 2 or where R 5 is H; and L is selected from the group consisting of:
,R
6
(CH
2 )r
R
R 89 and a C 6 -1o heterocyclic ring system substituted by R 8 and R 9 and containing 1-4 heteroatoms selected from N, S and 0; where r is an integer from 0-1; R 6 and R 7 are independently selected from the group consisting of H, C 1 .6alkyl, aryl, C.6alkylaryl, -COOR 0 -CONRi'R", -CN and -CF 3
R
8 and R 9 are independently selected from the group consisting of H, C 6 alkyl, aryl, C.6alkylaryl, C-4alkyloxy, halogen, -NO 2
-NRI'R",
-NR'oCOR", -O-CORO, -COOR'O, -CONR'OR", -CN, -CF3, -SO 2 NR'OR" and C 6 alkyl-O-Rl 0 and R' 1 and R" are independently selected from the group consisting of H, C 1 6 alkyl, Ci.3alkylaryl and aryl; and all optical isomers thereof.
A preferred embodiment of compounds of general formula II have the following stereochemistry: WO 98/16525 PCT/US97/18647 HN NH2
NH
(CH2)q 1 Ns
L
A- (CH 2
(CH
2 yNN iL 0 H 0 In yet another embodiment of the invention, R' and R 2 are H, p=3, s=0, K is a direct link, E is -NHC(=NH)-NH 2 and Y is -CO-G, where G is a group having the formula:
N
L
where J is and L is the group: R8 R9 where R 8 and R 9 are H. This is also illustrated as a preferred group of compounds defined by the general structural formula III as: HN NH 2
NH
A-(CH
2 2 n
S
O H O wherein: m is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2; WO 98/16525 A is selected from the group consisting of R 3
-NR
3
R
4 NH
NH
N
NH
2
NH
H
PCTIUS97/18647
NH
NK R16
H
NH
LR
17
NH
and S
,NH
2 s NI where R 3
R
4
R
1 6 and R 1 7 are independently selected from the group consisting of H, -OH and C 1 6 alkyl; W is C 1 6 alkyl, C 3 8 cycloalkyl, C 1 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; with the proviso that when A is R 3 then W must contain at least one N atom; and all optical isomers thereof.
A preferred embodiment of compounds of general formula III have the following stereochemistry:
(CH
2 )q N A- (CH 2
(CH
2 n ,r N Nf S O H O This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II and III. In addition, the compounds of formulas I, II and III can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and tautomers.
WO 98/16525 PCT/US97/18647 The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
This invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions.
Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992). Prodrugs commonly known in the art include acid derivatives well known to WO 98/16525 PCT/US97/18647 practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
The following structures are illustrative of the compounds of the present invention and are not intended to be limiting in any manner: 0 H HN NH2
NH
0 H HNNH2 HN 0 H S HNNH2
NH
HN YNH2 H2N HN NHg
NH
o HO HN NH2
NH
H2N r
N
0 H O HN.-NH2 NH NH H2N o HO HN NH 2 NH NNH o HO HN NH2 NH
NH
NH
0 H O HN NH2
NH
NH
NNCF-
H 0 H O WO 98/16525 PCT/US97/18647 HN lyNH 2
NHS
H 0 HNtNH 2
NH
0% N -,N Nr 0 HN. NH2
NH
H
2 N H 0 H N yNH 2
NH
0 4
H
2 N Ky%4 HN kNH 2 H2N 0 NH 0
HNZ.NH
2 NH
NH
H2N 0 HO0 HNyNH 2 0o HN VNH2 0 H3 CTNo 0 HN NH2
N
HN -J 0 H
NH
2 HN lyNH2
NH
NH 0 Ho HN NH2
NH
N Q~ X H30.YN 0 H 0
NH
HN N H2
-NH
HNyt NF42
NH-
H
2 N I
NH
WO 98/16525 HN NH 2
NH
HN Q 0 4 N- 0 H 0 HNyNH 2
NH
HNJ 0 H 0 HN Y.NH2
NH
NH 0 N 0 NH 0 H 0 PCT/US97/18647 HNrNH 2
NH
N N I N RN 0 H 0
NHN
HN
NH
2
NNH
HHC-9 0 H 0
H
3
C
HN YNH2
NH
N
H O NH 0 H 0 As mentioned above, the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.
Accordingly, a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention. In addition to the disease states noted above, other diseases treatable or preventable by the administration WO 98/16525 PCTIUS97/18647 of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.
The compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.
The compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin: The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects.
The compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the in vitro protease activity assays and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.
Diagnostic applications of the compounds of this invention will typically utilize WO 98/16525 PCT/US97/18647 formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles.
Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Gennaro edit.
1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
Dosage formulations of the compounds of this invention to be used for therapeutic WO 98/16525 PCT/US97/18647 administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods.
Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.
The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled.release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic WO 98/16525 PCT/US97/18647 acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents. tubing, prostheses and the like.
Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each compound by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is;, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
The compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg, preferably about to 50 mg/kg and more preferably about 1 to 20 mg/kg on a regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.
Typically, about 5 to 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
WO 98/16525 PCTIUS97/18647 The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
Typical adjuvants which may be incorporated into tablets, capsules and the like are binders suchas acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents.
When a dosage form is a capsule, in addition to the above materials it may also contain liquid carriers such as water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired.
Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
Preparation of the Disclosed Compounds The compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, et al., Eds., Springer-Verlag, Berlin, 1984.
Starting materials used in any of these methods arecommercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.
Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
During the synthesis of these compounds, the functional groups of the amino acid derivatives used in these methods are protected by blocking groups to prevent cross WO 98/16525 PCT/US97/18647 reaction during the coupling procedure. Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol.
3 (Gross, et al., Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.
Two exemplary synthesis schemes are outlined directly below, and the specific syntheses are described in the Examples. The reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be further purified by column chromatography (reversed-phase HPLC) or other appropriate methods.
HN
NH
2
NH
(CH2)q
A-(CH
2 )m-W-(CH 2 )n N S 0 0 Fragment -1 Fragment-2 Formula IV The peptide derivatives can be prepared by coupling of protected Fragment-I (Scheme 1) to protected Fragment-2 (Scheme The protecting groups are finally removed by HF-cleavage.
Most compounds are purified by reversed-phase HPLC and characterized by ionspray MS spectrometry Scheme I Preparation of Fragment-1 OH BOC-N 0 WO 98/16525 WO 9816525PCT/US97/18647 OH (Boc) 2
O
HN Bc El BOC' No 0
OH
Swern 0CNo
H
Witting Boc' 0
H
2 BOC, YoEt
LDA
CH
2
=CHCN
1. aq. NaOH 2. Cyciization
BOP
NaN(TMS) 2 BrCH 2 000Et aq. NaOH 0Q N
OH
Boc'NrQ
N
Scheme 11 Synthesis of Fragment-2 and Final Inhibitor HO0 Bo -A
BOP
NH MeNHOMe HN JNH-Tos HO0 Boe 'XNOMe
>NH
HN NH-Tos U-4 HO0 BrN
AS
>NH
HN NH-Tos 05/12 '01 17:11 FAX 61 2 9810 8200 F.B. RICE CO. 4 PATENTS Q019
HO
BsOP TFA N COOH ti combined with other techniques that are well known in the ant to produce other
NH
HN NM-Tos HNyNH-T0S HNy H H *j S Boo-N ON Hq N0 *g:o 5 The chemical reactions described in Schemes I and 11 can easily be modified and combined with other techniques that are well known in the art to produce other compounds within the family of formula 1.
Methods of incorporating substituents such as R 3
-NR
3
R';
NR
15 3 RNRSR1 14
R'
GO 0: NR's NRIs *aa*a and G N R6 R)LR R 1 14 Re 3 are well known in the art The chemisty of using the various R substituents -O- C1alkyl and C1-alkylaryl) is also well known in the art Methods of incorporating "W" substituents such as CI-alkyl, C34cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected frorn the group consistirig of N, O and S, are also well known in the art In addition, and substituents are illustrated in Example 13.
The "R substituent illustrated in Fragments -I and -2 is Fragments similar to these structures, where R' is Ci-6alkyl C34cycloalkyl, C1.3alkylaryl, or aryl, can easily be synthesized by techniques that are well known in the art. See, for example, Duggan, et WO 98/16525 PCT/US97/18 6 4 7 al., U.S. Patent No. 5,281,585.
The substituent illustrated in Fragment-2
(-NHC(=NH)-NH
2 is merely illustrative of one of the various substituents encompassed by the invention.
Fragments similar to the structure of Fragment-2, where E is -NH2,
-SC(=NH)-NH
2 or -C(=NH)-NH2, can easily be synthesized by techniques that are well known in the art.
The substituent illustrated in Fragment-2 is -CO-G, where G is:
N
L
where: J is and L is
R
8
R
and R and
R
9 are H. Fragments similar to the structure of Fragment-2, where G is:
N
\L
and J is -SO- or -SO 2 can easily be synthesized by techniques that are well known in the art. Fragments where J is can be synthesized by techniques illustrated in J. Am.
hem Soc. 114: 1854-1863 (1992), Med. Chem. 38:76-85 (1995), and J. Med. Chem: 37:3492-3502 (1994) Lastly, fragments where J is -NR 5 where R5 is H, CIalkyl or benzyl, can be synthesized by techniques illustrated in Chem. 37:3492-3502 (1994). All of these references are incorporated herein by reference.
Fragments similar to the structure of Fragment-2, where G is:
N
JL
05/12 '01 17:11 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS 2020 and L is: R
R
(CH
2 or
R
9 where R 6
R
7
R
8 and R 9 are not H, can also be easily synthesized by techniques that are well known in the art.
Fragments similar to the sructure of Fragment-2, where G is H, -COOR -CONIR°'R -CF 3 or -CF 2 CF3, can easily be synthesized by techniques that are well known in the art.
,Fragments similar to the structure of Fragment-2, where G is: S 10 and U and V are the various substituents can also easily be synthesized by well known techniques illustrated inJ. Med. Chem. 38: 1355-1371 (1995) and J. Med. Chemn 37:2421-2436 (1994).
Fragments similar to the structure of Fragment-2, where is a boron-containing group can easily be synthesized by techniques that are well known in the art. See for example, J. Org- Chem. 60:3717-3722 (1995).
The mechanisms for coupling the fragments used to synthesize the compounds of the instant invention, are also well known in the art Without further elaboration; it is believed that one skilled in the art can utilized the present invention to its fullest extent. Therefore, the following preferred specific embodiments are to be construed as merely illustrative and do not limit the remainder of the disclosure in any way whatsoever.
WO 98/16525 PCT/US97/18647 EXAMPLE 1 Preparation of Boc-Arg(Tos)-N(Me)OMe H O BoC OMe CH3
NH
HN NH-Tos To a suspension of Boc-Arg(Tos)-OH (2 g, 4.7 mmol) in DMF (20 mL) at 0°C is added MeNHOMe.HCI (1 g, 10.3 mmol), DIEA (6 mL) and BOP (2.5 g, 5.6 mmol). The solution is stirred at 0 C for 10 h. DMF is evaporated by vacuum. The oily residue is dissolved in EtOAc (200 mL) and water (20 mL). The organic layer is washed with sat.
NaHCO3, water (20 mL), 1 M HC1 10 mL) and sat. NaCI (2 X 20 mL). The organic layer is dried over MgSO 4 filtered and evaporated to give a suspension. The suspension is filtered, washed with cold EtOAc (10 mL) and dried to give Boc-Arg(Tos)-N(Me)OMe g, 70 yield). FAB-MS 472 EXAMPLE 2 Preparation of Boc-Arg(Tos)-Thiazole H O BocNS
N
NH
HN NH-Tos To a solution of thiazole (2.5 g, 29 mmol) in THF (25 mL) at -78 0 C is added n-BuLi (1.6 M in hexane, 19 mL) dropwise. The mixture is stirred for 30 min. Then a solution of Boc-Arg(Tos)-N(Me)OMe (1.7 g, 3.6 mmol) in THF (50 mL) is added to the lithiothiazole mixture at -78 0 C. The solution is stirred for 2 h. 1M HCI (30 mL) is added to the reaction mixture and warmed to room temperature. The mixture is extracted with EtOAc (100 mL). The organic layer is washed with sat. NaCI (30 mL), dried over WO 98/16525 PCTIUS97/18647 MgSO 4 filtered and evaporated. The crude oily residue is purified by flash column over SiO 2 (50% EtOAc in CH 2
CI
2 to give Boc-Arg(Tos)-Thiazole (1.5 g, 84% yield) as a powder. DCI -MS (M+H) 496 EXAMPLE 3 Preparation of H-Arg(Tos)-Thiazole H O TFA H N S
N
NH
HN NH-Tos To a solution of Boc-Arg(Tos)-Thiazole (300 mg, 0.6 mmol) in CH 2
CI
2 (10 mL) at 0°C is added TFA (10 mL). The solution is stirred at 0°C for 2 h. The solvent and excess TFA are evaporated to an oily residue which is used directly without further purification.
EXAMPLE 4 Preparation of N-Boc-4-piperidineethanol BocN A stirred solution of 4-piperidineethanol (1.87 g, 14 mmol) and DMF (5 mL) at 0 C is treated with N-t-butoxycarbonyl anhydride (3 g, 14 mmol). After 1 h, the cooling bath is removed and the reaction mixture stirred for an additional 20 h. The reaction mixture is then diluted with ether, and concentrated to furnish the title compound (2.6 g, 82%) as a colorless oil.
EXAMPLE Preparation of Ethyl 4-(N-Boc-piperidin-4-yl)-trans-crotonate WO 98/16525 PCT/US97/18647 rOEt Boc N
OE
To a stirred solution of oxalyl chloride (0.43 mL, 5.0 mmol) in CHC1 2 (30 mL) at 78 0 C is added DMSO (0.52 mL, 7.0 mmol) dropwise. After gas evolution subsided min), the alcohol of Example 4 (0.8 g, 3.5 mmol) in CH 2
CI
2 (20 mL) is added in a stream.
After 20 min, (carbethoxymethylene) triphenyl-phosphorane (1.4 g, 4.0 mmol) is added.
After 2 h, the reaction mixture is diluted with petroleum ether, washed with water,
KHSO
4 and sat. NaCI, dried over MgSO 4 and concentrated. Flash column chromatography (15% EtOAc in hexane) gave the title compound (0.57 g, 38%) as a colorless oil.
EXAMPLE 6 Preparation of Ethyl 4-(N-Boc-piperdin-4-yl)butyrate 3 OEt Boc^ N 0 The olefin of Example 5 (2.6 g, 8.7 mmol) in EtOAc (50 mL) at room temperature is stirred under a hydrogen atmosphere (1 atm) in the presence of 10% Pd/C (500 mg) overnight. The reaction mixture is then purged with argon, followed by filtration through a Celite pad. Concentration of the filtrate followed by flash chromatography EtOAc in hexane) gave the title ester (2.4 g, 92%) as a crystalline solid.
EXAMPLE 7 Preparation of:
CN
OEt Boc N 0 To a solution of TiCl 4 (4.2 mL, 4.2 mmol, 1 M in CH 2 Cl 2 and CH 2 Cl 2 (25 mL) at 0oC WO 98/16525 PCT/US97/18647 is added titanium isopropoxide (0.42 mL, 1.4 mmol). After 15 min, diisopropylethylamine (1 mL, 6.3 mmol) is added dropwise to form a solution. After min, the ester of Example 6 (5 mmol) in CH 2 C1 2 (7 mL) is added, followed by stirring at 0 C for 1 h. Acrylonitrile (3.3 mL, 50 mmol) is added dropwise at 0°C to the solution.
After 4 h, the reaction is quenched with sat. NH 4 CI (15 mL) at 0°C and then the mixture extracted with CH 2 Cl 2 The combined organic extracts are washed with sat. NaHCO 3 and sat. NaC1, dried over MgSO 4 and concentrated. Flash column chromatography gives the compound shown above, as an oil.
EXAMPLE 8 Preparation of:
NH
2
HCI
OrEt BocN 0 O A mixture of the compound of Example 7 (40 mmol), PtO 2 (2.0 MeOH (70 mL) and CHC1 3 (7 mL) is shaken on the Parr apparatus under a hydrogen atmosphere (60 psi) at room temperature for 3 h. The reaction mixture is filtered through a Celite pad and concentrated to furnish the crude amine HCI as a solid.
EXAMPLE 9 Preparation of:
NH
Boc^ N The crude amine.HC1 of Example 8 (10 mmol), acetonitrile (75 mL), and NaHCO 3 (3 g) is stirred at room temperature for 20 h. The heterogeneous mixture is then filtered and filtrate concentrated. Flash chromatography gives the compound shown above, as a powder.
WO 98/16525 PCT/US97/18647 EXAMPLE Preparation of:
O
NBOc- OEt BocN O To a stirred solution of the title compound of Example 9 (6 g, 22 mmol) and THF mL) at -78 0 C is added NaN(TMS) 2 (24.5 mL, 24.5 mmol, 1 M in hexane) dropwise.
After 15 min, ethyl bromoacetate (5.2 mL, 45 mmol) is added and then the reaction mixture warmed to 0°C for 1 h. The reaction is quenched with HOAc (1.0 mL) and then the mixture diluted with EtOAc, washed with water and sat. NaCI, dried over MgSO 4 and concentrated. Flash chromatography (40% EtOAc in hexane) gave the compound shown above (7.6 g, as an oil.
EXAMPLE 11 Preparation of: N
OH
Boc" 0 A solution of the compound of Example 10 (6.0 g, 15 mmol), IN NaOH (50 mL, mmol), and MeOH (75 mL) is stirred at room temperature for 1 h. The reaction mixture is then acidified with 5% KHSO 4 and then extracted with EtOAc. The organic portion is washed with sat. NaCI, dried over MgSO 4 and concentrated to give the compound shown above (5.6 g, 100%), as an oil.
EXAMPLE 12 Preparation of: WO 98/16525 PCTIUS97/18647 HN NH-Tos
NH
Boc/ 0 The compounds of Example 11 (1 mmol) and Example 3 (1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C. The solution is neutralized with DIEA (1 mL) followed by the addition of coupling reagent BOP (1.1 mmol). The solution is stirred for 1-2 h and HPLC analysis shows the completion of reaction. Solvent is removed by vacuum at 0 C. The residue is dissolved in a mixture of EtOAc-H 2 0 (50 mL: 10 mL) and aqueous layer is discarded. The organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCI (2 X 10 mL), dried over MgSO 4 filtered and evaporated. The oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
EXAMPLE 13 Preparation of: HN Y NH 2
NH
0 H N 100 mg of the compound of Example 12, 1 ml of anisole and 4 drops of MeSEt are placed in HF-cleavage vessel and cooled under liquid N 2 10 ml of HF is then condensed and the mixture is stirred at 0°C for 1.25 h. HF is removed under vacuum to give a gumlike residue. The residue is triturated with 20 ml of 50% Et 2 O-hexane and the solvent removed by filtration. The gum residue is dissolved in 30 ml of 30% aq. HOAc and filtered through the above sintered funnel. The filtrate is lyophilized to give a powder WO 98/16525 PCT/US97/18647 which is purified by RP-HPLC to give the compound shown above, as a powder.
EXAMPLE 14 (Determination of ICs The compounds of the present invention are first dissolved in a buffer to give solutions containing concentrations such that assay concentrations range from 0-100 pIM.
In assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate would be added to a solution containing a test compound and the enzyme of interest and the residual catalytic activity of that enzyme would then be determined spectrophotometrically.
The ICo 5 of a compound is determined from the substrate turnover. The ICo 5 is the concentration of test compound giving 50% inhibition of the substrate turnover.
Preferred compounds of the invention desirably have an IC 50 of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferably less than 100 nM.
Preferred compounds of the invention desirably have an ICo 5 of less than 4.0 pgM in the prothrombinase assay, preferably less than 200 nM, and more preferably less than nM. Preferred compounds of the invention desirably have an ICo 5 of greater than 1.0 R.M in the thrombin assay, preferably greater than 10.0 gM, and more preferably greater than 100.0 pM.
Amidolvtic Assays for determining protease inhibition activity Factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris HCI buffer, pH 7.5, containing 0.15 M NaCl. The rates of hydrolysis of the paranitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with the test compound for 5 minutes at room temperature are determined using a Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroanilide.
The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method as described by Sinha, et al., Thromb. Res., 75:427-436 WO 98/16525 PCT/US97/18647 (1994). The activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of a 5 minute preincubation of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 in 20 mM Tris HCI buffer, pH containing 0.15 M NaCI, 5 mM CaC12 and 0.1% bovine serum albumin. Aliquots from the complex-test compdund mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Several concentrations of a given test compound are assayed in duplicate.
A standard curve of thrombin generation by an equivalent amount of untreated complex is then used for determination of percent inhibition.
EXAMPLE The antithrombotic efficacy of the compounds of this invention can readily be evaluated using a series of studies in rabbits, as described below. These studies are also useful in evaluating a compounds effects on hemostasis and its the hematological parameters.
Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis A rabbit deep vein thrombosis model as described by Hollenbach, et al., Thromb.
Haemost. 71:357-362 (1994), is used to determine the in vivo antithrombotic activity of the compounds of the present invention. Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail.
A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A nonocclusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is then used as a measure of the antithrombotic activity of the compound being evaluated. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and WO 98/16525 PCT/US97/18647 during steady state infusion of the compound being evaluated. Initiation of thrombus formation will begin immediately after advancement of the cotton thread apparatus into the central venous circulation. The compounds being evaluated are administered from minutes to time= 150 minutes at which point the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are then analyzed for changes in hematological and coagulation parameters.
Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention.
Accordingly, the invention is limited only by the following claims.
Claims (33)
1. A compound having the formula: E (OH 2 0 A-(CH 2 )m-W(CH 2 )n N H 2 (I 0 R 1 ,R 2 wherein: R' is H, C 1 6 alkyl, C 3 6 cycloalkyl, C 1 3 alkylaryl, C 1 3 alkyl-C 3 8 cycloalkyl or aryl and R(2 is H, CI. 6 alkyI, or R(1 and R 2 are taken together to form a carbocyclic ring; m is an integer from 0-3; n is an integer from 0-6; p is an integer from 0-4; s is an integer from 0-2; q is an integer from 0-2; A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S; R(3; -NR 3 R 4 NR 15 NR 1 NR 1 5 NR 1 5 NR 1 N>"X R 1; and S'N R1 where R(4, R(14 and R(15 are independently selected from the group consisting of H, WO 98/16525 PCT/US97/18647 -OH, Ci-6alkyl, aryl and C.4alkylaryl; R 1 6 is selected from the group consisting of H, -OH, Ci.6alkyl, aryl and C 1 .4alkylaryl, or can be taken together with R 14 or R 15 to form a
5-6 membered ring; and R 17 is selected from the group consisting of H, -OH, CI. 6 alkyl, aryl and C.4alkylaryl, or can be taken together with R 1 to form a 5-6 membered ring; W is Ci.6alkyl, C 3 8 cycloalkyl, Ci. 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; K is selected from the group consisting of a direct link, C 3 .scycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; E is selected from the group consisting of R 2 6 -NR 26 R 27 NR 29 NR 29 N NR26R30 N R26Rj' R28 NR 29 NR 29 NR 29 \N R3 0 and R28 R31 'S NR26R31 R 28 where R 26 R 27 R 2 8 and R 29 are independently selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and C 1 i4alkylaryl; R 30 is selected from the group consisting of H, C 1 6 alkyl, aryl and C 1 4alkylaryl, or can be taken together with R 28 or R 29 to form a 5-6 membered ring; and R 3 1 is selected from the group consisting of H, C.6alkyl, aryl and C 1 4alkylaryl, or can be taken together with R 2 9 to form a 5-6 membered ring; with the proviso that when E is R 26 then K must contain at least one N atom; Y is selected from the group consisting of H, 05/12 '01 17:11 FAX 61 2 9810 8200 F.B. RICE CO. PATENTS Z021 H 3 ,OR" H 3 -8 C 3 3: and ,BOR 1 1H H3 a CH3 CH 3 where R' 2 and R' 3 are independently selected from the group consisting of H. C,. 3 alkyl and aryl; and G is H -COOR00 -CONRO -CF 2 CF 3 or a group having the formula- or L where: .R is selected from the group consisting of H, C.alkyl, Cz 4 alkenyl, Cgalkylaryl, C 24 alkenylaryL C4alkylheterocyclo, C 2 46aUcenylheterocyclo, -CF 3 and -CFCFj; J is -SO 2 or where R' is H, C 14 alkyl or benzyl; and 10 L is selected from the group consisting of: R Ra Re and R7 R9 a C 0 lo heterocyclic ring system substituted by Ra and R9 and containing 1-4 heteroatoms selected from N, S and 0; where r is an integer from 0-2; R' and R7 are independently selected from the group consisting of H, Calkyl, aryl, C 1 -alkylaryl, -COOR'o -CONR'oR", -CN and -CF 3 R' and R9 are independently selected from the group consisting of H, CI-alkyl, aryl, C 1 s6alkylaryl, Ci.alkyloxy, halogen, -NO 2 -NR'OR", -NR' 0 COR", -0-R' 0 -O-COR' 0 -COOR'O, -CONR' 0 -CN, -CF 3 -SO 2 NR'OR" and C 1 alkyl-O-Ro 0 and Ro and R" are independently selected from the group consisting of H. C 4 alkcyl. C-3alkylaryl and aryl; 05/12 '01 17:12 FAX 61 2 9810 8200 F.B. RICE CO. 4 PATENTS 2022 U is or and V is or with the proviso that at least one of U or V. is or and all optical isomers thereof. 2. The compound ofClaim I where R is H or C 4 alkyI 0O@* 0 *09* 0@ 3. the compound of Claim 1 where R 2 is H. 10 4. The compound of Claim 1 where m is an integer from 0-1. 5. The compound of Claim 1 where n is an integer from 1-4.
6. The compound of Claim I where p is 3. 0 0 0 0 0 0 *0 0 0 0 20
7. The compound of Claim 1 where s is 0.
8. The compound of Claim I where q is an integer from 0-1.
9. The compound of Claim 1 where A is selected from the group consisting of R 3 -NR 3 R 4 NR s 15 N.,NNR3R16 414 NR 1 "I'KNR3R17 NR 1 and NR1 7 The compound of Claim 9 where R 3 is H, -OH or C_ alkyl. WO 98/16525
11. The compound of Claim 9 where R 4 is H, -OH or C 1 6 alkyl. PCT/US97/18647
12. The compound of Claim 1 where W is CI.4alkyl, Cs. 6 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom.
13. The compound of Claim 1 where K is a direct link.
14. The compound of Claim I where E is -NH 2 -NHC(=NH)-NH2 or -SC(=NH)-NH 2 The compound of Claim 1 where Y is: OR 12 -B OR13 0
16. The compound of Claim 15 where R 1 2 is H.
17. The compound of Claim 15 where R 13 is H.
18. The compound of Claim 15 where G is a group having the formula: N L
19. The compound of Claim 18 where J is or -NR 5 The compound of Claim 19 where R 5 is H.
21. The compound of Claim 18 where L is: WO 98/16525 WO 9816525PCTIUS97/18647 R 8 R 8 ori
22. The compound of Claim 21 where R 8 is H, -O-R' 0 -COOR' 0 -CONR' 0 R" or -CF 3
23. The compound of Claim 21 where R 9 is H, -O-R' 0 -COOR' 0 -CONR' 0 or -CF 3
24. The compound of Claim 1 where R' 0 is H. The compound of Claim 1 where R" is H.
26. A compound having the formula: HN yNH2 NH (CH2)q 0 IN A-(CH 2 )mdW (H 2 N NL 0 H 0 wherein: m is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2; A is selected from the group consisting of R 3 -NR 3 R 4 WO 98/16525 WO 9816525PCT/US97/18647 NR' 5 NR 1 ~N )LINR3R16; N R 3R17 14 NR 15 NR 15 NR 1 1 ~K14 R 17 an S) N R 3R 17 where R 4 R 1 4 and R1 5 are independently selected from the group consisting of H, -OH, C 1 6 alkyl, aryl and C 14 alkylaryl; R'1 6 is selected from the group consisting of H, -OH, C 1 6 alkyI, aryl and C 1 4alkylaryl, or can be taken together with R 1 4 or R5to form a 5-6 membered ring; and R 1 7 is selected from the group consisting of H, -OH, C 1 6 alkyl. aryl and C 14 alkylaryI, or can be taken together with R's to form a 5-6 membered ring; W is C 16 alkyl, C 3 8 CYCloalkyl, CI- 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S; with the proviso that when A is R 3 then W must contain at least one N atom; J is -SO 2 or -NR5-, where R5 is H; and L is selected from the group consisting of: R R 8 R (CH 2 )r and R 7 R99 a C 6 1 0 heterocyclic ring system substituted by R 8 and R? and containing 1-4 heteroatoms selected from N, S and 0; where r is an integer from 0-1; R 6 and R 7 are independently selected from the group consisting of H, C 1 6 alkyl, aryl, C 1 6 alkylaryl, -COOR' 0 -CONR' 0 -CN and -CF 3 R 8 and R 9 are independently selected from the group consisting of H, C 16 alkyl, aryl, C 1 -alkylaryl, C 1 .4akyloxy, halogen, -NO 2 -NR' 0 R" -NR' 0 COR", -O-R' 0 -O-COR' 0 -COOR' 0 -CONR' 0 -CN, -CF 3 -SO 2 NR' 0 R" and C 1 6 alkyl-O-R' 0 and R' 0 and R" are independently selected from the group consisting of WO 98/16525 PCT/US97/18647 H, Ci. 6 alkyl, Ci. 3 alkylaryl and aryl; and all optical isomers thereof.
27. The compound of Claim 26 where A is R 3 -NR 3 R 4 NR 15 NR15 N R NR3R6 NR 3 R 1 7 F14 NR 1 and R 'S NR 3 R 17
28. The compound of Claim 27 where R 3 and R 4 are independently selected from the group consisting of H, -OH and methyl.
29. The compound of Claim 26 where W is CI.4alkyl, C5-6cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom. The compound of Claim 26 where J is or -NR 5 where R 5 is H.
31. The compound of Claim 26 where L is: R 8 R 9
32. The compound of Claim 31 where R 8 is H, -O-R 0 -COOR 1 0 -CONRIoR" or -CF 3
33. The compound of Claim 31 where R 9 is H, -O-R 1 0 -COOR' 1 -CONR'i°R" or -CF 3
34. The compound of Claim 26 having the following stereochemistry: WO 98/16525 WO 9816525PCT/US97/18647 HN YNH 2 NH (CH2)q 0N N~N /IN L A- (CH -m (OH 2 O HO0 A compound having the formula: HN NH2 NH (CH 2 )q A- (CHW (OH "A N N oH 0 wherein: m is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2; A is selected from the group consisting of -NR 3 R 4 NH NH N NH 2 NH H NH NH NH NA- R 16 and H NH 2 where R 3 R R' 6 and R 1 7 are independently selected from the group consisting of H, -OH WO 98/16525 PCT/US97/18647 and Cl. 6 alkyl; W is C.- 6 alkyl, C 3 8 cycloalkyl, C 1 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; ivith the proviso that when A is R 3 then W must contain at least one N atom; and all optical isomers thereof.
36. The compound of Claim 35 where A is selected from the group consisting of R 3 NR 3 R 4 NH J| NH NH N NH 2 NH 2 and S NH H 2
37. The compound of Claim 36 where R 3 and R 4 are independently selected from the group consisting of H, -OH and methyl.
38. The compound of Claim 35 where W is C 1 -4alkyl, Cs. 6 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom.
39. The compound of Claim 35 having the following stereochemistry: HN NH 2 NH (CH2)q A- (CH 2 (CH 2 n N S A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and the compound of any one of claims 1 to
41. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of the compound of any one of claims 1 to
42. The method of claim 41, wherein the condition is selected from the group consisting of: the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic 15 stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral 20 arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy. 25 43. A method for inhibiting the coagulation of biological samples, the method comprising the administration of the compound of any one of claims 1 to
44. A use of the compound of any one of claims 1 to 25 for the preparation of a medicament for preventing or treating a condition in a mammal characterized by undesired thrombosis. The use according to claim 44, wherein the condition is selected from the group consisting of: the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy. Dated this sixth day of December 1999 COR THERAPEUTICS, INC Patent Attorneys for the Applicant: FBRICE CO i Fo *o
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73136196A | 1996-10-11 | 1996-10-11 | |
US3515496P | 1996-10-11 | 1996-10-11 | |
US60/035154 | 1996-10-11 | ||
US08/731361 | 1996-10-11 | ||
PCT/US1997/018647 WO1998016525A1 (en) | 1996-10-11 | 1997-10-10 | SELECTIVE FACTOR Xa INHIBITORS |
US08/948,482 US6194435B1 (en) | 1996-10-11 | 1997-10-10 | Lactams as selective factor Xa inhibitors |
US08/948482 | 1997-10-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4904797A AU4904797A (en) | 1998-05-11 |
AU743544B2 true AU743544B2 (en) | 2002-01-31 |
Family
ID=27364800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU49047/97A Ceased AU743544B2 (en) | 1996-10-11 | 1997-10-10 | Selective factor Xa inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0932608A1 (en) |
JP (1) | JP2001502674A (en) |
AU (1) | AU743544B2 (en) |
CA (1) | CA2268264A1 (en) |
WO (1) | WO1998016525A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6297233B1 (en) | 1999-02-09 | 2001-10-02 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6750342B1 (en) | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
AU771928B2 (en) * | 1999-05-19 | 2004-04-08 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
US6852761B2 (en) | 2000-03-13 | 2005-02-08 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
JP2004505013A (en) | 2000-04-05 | 2004-02-19 | ファルマシア・コーポレーション | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selectively inhibiting the coagulation cascade |
WO2001077097A2 (en) | 2000-04-05 | 2001-10-18 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
AU2001253363A1 (en) | 2000-04-17 | 2001-10-30 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
EP1351686A2 (en) | 2000-11-20 | 2003-10-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
US6969715B2 (en) | 2001-10-03 | 2005-11-29 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
MXPA04003170A (en) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade. |
AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
JPH10503176A (en) * | 1994-06-17 | 1998-03-24 | コーバス インターナショナル, インコーポレイテッド | 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors |
US5932733A (en) * | 1994-06-17 | 1999-08-03 | Corvas International, Inc. | 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors |
DE69526677T2 (en) * | 1994-12-13 | 2002-12-05 | Corvas Int Inc | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYMINHIBITORS |
AU4250896A (en) * | 1994-12-22 | 1996-07-10 | Biochem Pharma Inc. | Heterocyclic keto arginine peptides as thrombin inhibitors |
US5523308A (en) * | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
-
1997
- 1997-10-10 AU AU49047/97A patent/AU743544B2/en not_active Ceased
- 1997-10-10 CA CA002268264A patent/CA2268264A1/en not_active Abandoned
- 1997-10-10 JP JP10518581A patent/JP2001502674A/en active Pending
- 1997-10-10 WO PCT/US1997/018647 patent/WO1998016525A1/en not_active Application Discontinuation
- 1997-10-10 EP EP97911745A patent/EP0932608A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO1998016525A1 (en) | 1998-04-23 |
EP0932608A1 (en) | 1999-08-04 |
CA2268264A1 (en) | 1998-04-23 |
AU4904797A (en) | 1998-05-11 |
JP2001502674A (en) | 2001-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU743544B2 (en) | Selective factor Xa inhibitors | |
EP0937073A2 (en) | Selective factor xa inhibitors | |
WO1998016547A1 (en) | SELECTIVE FACTOR Xa INHIBITORS | |
WO1998016523A9 (en) | Selective factor xa inhibitors | |
US6204268B1 (en) | Selective factor Xa inhibitors | |
US6211183B1 (en) | Selective factor Xa inhibitors | |
US6262047B1 (en) | Selective factor Xa inhibitors | |
EP0994893B1 (en) | Selective factor xa inhibitors containing a fused azepinone structure | |
AU741099B2 (en) | Selective factor Xa inhibitors | |
US6369063B1 (en) | Selective factor Xa inhibitors | |
US6525076B1 (en) | Selective factor Xa inhibitors | |
US6333321B1 (en) | Selective factor Xa inhibitors | |
US6228854B1 (en) | Selective factor Xa inhibitors | |
US6369080B2 (en) | Selective factor Xa inhibitors | |
US6194435B1 (en) | Lactams as selective factor Xa inhibitors | |
WO1998016524A1 (en) | HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS | |
US6218382B1 (en) | Selective factor Xa inhibitors | |
AU720513C (en) | Selective factor Xa inhibitors | |
AU743614B2 (en) | Heterocyclic derivatives as factor Xa inhibitors | |
AU746596B2 (en) | Selective factor Xa inhibitors | |
AU753842B2 (en) | Selective factor Xa inhibitors | |
AU9713401A (en) | Heterocyclic derivatives as factor Xa inhibitors | |
AU8826998A (en) | Selective factor xa inhibitors containing a fused azepinone structure | |
AU8827098A (en) | Selective factor xa inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: MILLENNIUM PHARMACEUTICALS, INC. Free format text: FORMER OWNER WAS: COR THERAPEUTICS, INC. |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |